phosphoramidic acid has been researched along with Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Angel, A; Congiatu, C; Gavazza, F; Jones, PA; Marquez, VE; McGuigan, C; Siddiqui, MA; Valente, R; Yoo, CB | 1 |
| Benny, P; Berkman, CE; Bryan, JN; Ganguly, T; He, H; Jabbes, M; Jewett, C; Liu, T; Nedrow-Byers, JR | 1 |
2 other study(ies) available for phosphoramidic acid and Adenocarcinoma
| Article | Year |
|---|---|
Activation of p16 gene silenced by DNA methylation in cancer cells by phosphoramidate derivatives of 2'-deoxyzebularine.
Topics: Adenocarcinoma; Amides; Cytidine; DCMP Deaminase; DNA Methylation; Dose-Response Relationship, Drug; Gene Silencing; Genes, p16; Humans; Molecular Structure; Pancreatic Neoplasms; Phosphoric Acids; Reverse Transcriptase Polymerase Chain Reaction; Stereoisomerism; Thymidylate Synthase; Tumor Cells, Cultured | 2008 |
A phosphoramidate-based prostate-specific membrane antigen-targeted SPECT agent.
Topics: Adenocarcinoma; Amides; Animals; Cell Line, Tumor; Humans; In Vitro Techniques; Male; Mice; Mice, Nude; Pentetic Acid; Phosphoric Acids; Prostate-Specific Antigen; Prostatic Neoplasms; Sensitivity and Specificity; Technetium; Time Factors; Tomography, Emission-Computed, Single-Photon; Transplantation, Heterologous | 2012 |